Inovio, Thermo Fisher partner to scale up production of COVID-19 vaccine candidate
Fox Business Flash top headlines for September 8
Fox Business Flash top headlines are here. Check out what’s clicking on FoxBusiness.com.
Inovio Pharmaceuticals announced Tuesday that Thermo Fisher Scientific will manufacture the company's experimental COVID-19 vaccine candidate.
Continue Reading Below
Amid the worldwide race to find a treatment, Thermo Fisher will effectively join other third-party manufacturers helping Inovio scale up production of its experimental vaccine, INO-4800.
CHINA'S CNBG, SINOVAC FIND MORE COUNTRIES TO TEST CORONAVIRUS VACCINES
The Pennsylvania biotech company plans to have 100 million doses of its vaccine in 2021 subject to "FDA approval of INO-4800 for use as a COVID-19 vaccine," Inovio said in its announcement, adding that Thermo Fisher will play a central role to hitting that mark.
If approved, it'll be a first for Inovio, which has never received FDA approval to bring a vaccine candidate to market throughout its history, according to multiple reports.
|TMO||THERMO FISHER SCIENTIFIC||405.30||-4.68||-1.14%|
"Thermo Fisher's global capabilities and scale will be central to our production progress – the organization's commitment to quality, reliable production will be key to our ability to meet the urgent, global demand for a safe and effective vaccine against COVID-19," Inovio CEO Dr. J. Joseph Kim said.
Thermo Fisher says it remains "extremely well-positioned to support Inovio on its mission" and that at peak capacity, it projects it could hit that 100 million mark annually.